论文部分内容阅读
研究上海市慢性乙型肝炎(CHB)病人血清HBeAb转归与疾病进展的关系。以回顾性队列研究方式,随访107例HBsAg和HBeAg均阳性的CHB患者HBeAb阳转、失代偿性肝硬化(DC)、肝癌(HCC)和死亡的发生情况,并进行生存分析。CHB病人的HBeAb人年阳转率为64.3‰。HBeAb(+)组和HBeAb(-)组的DC、HCC、死亡人年率分别为7.4‰、0‰、4.4‰和20.5‰、13.2‰、30.6‰。两组不发生HCC率和生存率曲线差别均有显著意义。慢性乙型肝炎病人HBeAb阳性组HCC和死亡的人年发生率低于HBeAb阴性组,且HCC和死亡的发生较迟。
To study the relationship between serum HBeAb level and disease progression in patients with chronic hepatitis B (CHB) in Shanghai. A retrospective cohort study was followed up for 107 HBeAg positive cases, decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and death in CHB patients who were positive for HBsAg and HBeAg. Survival analysis was performed. CHB patients HBeAb annual positive rate of 64.3 ‰. The annual rates of DC, HCC and death of HBeAb (+) and HBeAb (-) groups were 7.4 ‰, 0 ‰, 4.4 ‰ and 20.5 ‰, 13.2 ‰ and 30.6 ‰, respectively. HCC rate did not occur in both groups and the difference between survival rates were significant. The annual incidence of HCC and death in HBeAb-positive patients with chronic hepatitis B is lower than in HBeAb-negative patients, and the incidence of HCC and death is late.